Here are the DEF 14A proxy statements from Anika Therapeutics Inc (ANIK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ANIK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIK filings page.
Anika Therapeutics, Inc. is asking stockholders to vote at its June 18, 2026 virtual annual meeting on five items: electing three Class III directors, ratifying Deloitte & Touche LLP as 2026 auditor, an advisory say‑on‑pay vote, and amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan.
The company reports 2025 growth led by its Commercial Channel, with Commercial revenue up 15% year over year and 22% in the fourth quarter, driven by international OA Pain Management and the Integrity Implant System. Hyalofast advanced toward a future U.S. launch following filing of the final PMA module and FDA feedback.
The board seeks to add 475,000 shares to the 2017 Omnibus Incentive Plan, bringing 1,269,928 shares reserved (8.8% of fully diluted common stock) and doubling the ESPP reserve from 200,000 to 400,000 shares. Governance highlights include a majority voting policy for uncontested director elections, fully independent key committees, and separation of Executive Chair, Lead Independent Director, and CEO roles.